NASDAQ:EIGR - Eiger Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eiger Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.74 -0.24 (-3.44 %) (As of 03/31/2020 02:16 AM ET) Add Compare Today's Range$6.54Now: $6.74▼$7.0950-Day Range$4.91MA: $8.77▼$11.9952-Week Range$4.55Now: $6.74▼$15.82Volume199,412 shsAverage Volume362,058 shsMarket Capitalization$165.53 millionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EIGR Previous Symbol CUSIPN/A CIK1305253 Webhttp://www.eigerbio.com/ Phone650-272-6138Debt Debt-to-Equity Ratio0.56 Current Ratio5.92 Quick Ratio5.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book2.92Profitability EPS (Most Recent Fiscal Year)($3.08) Net Income$-70,250,000.00 Net MarginsN/A Return on Equity-105.24% Return on Assets-62.28%Miscellaneous Employees18 Outstanding Shares24,559,000Market Cap$165.53 million Next Earnings Date5/14/2020 (Estimated) OptionableNot Optionable Receive EIGR News and Ratings via Email Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EIGR Rates by TradingView Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions How has Eiger Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Eiger Biopharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EIGR shares have decreased by 1.0% and is now trading at $6.74. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Eiger Biopharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eiger Biopharmaceuticals. When is Eiger Biopharmaceuticals' next earnings date? Eiger Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Eiger Biopharmaceuticals. How were Eiger Biopharmaceuticals' earnings last quarter? Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) released its earnings results on Friday, March, 13th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.30. View Eiger Biopharmaceuticals' earnings history. What price target have analysts set for EIGR? 5 brokers have issued 1 year price targets for Eiger Biopharmaceuticals' shares. Their forecasts range from $10.72 to $35.00. On average, they anticipate Eiger Biopharmaceuticals' stock price to reach $24.68 in the next twelve months. This suggests a possible upside of 266.2% from the stock's current price. View analysts' price targets for Eiger Biopharmaceuticals. What are Wall Street analysts saying about Eiger Biopharmaceuticals stock? Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock: 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (1/27/2020) 2. LADENBURG THALM/SH SH analysts commented, "We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs." (8/12/2019) Has Eiger Biopharmaceuticals been receiving favorable news coverage? Media stories about EIGR stock have been trending very negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eiger Biopharmaceuticals earned a news impact score of -3.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutEiger Biopharmaceuticals. Are investors shorting Eiger Biopharmaceuticals? Eiger Biopharmaceuticals saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 961,600 shares, an increase of 14.5% from the February 27th total of 840,100 shares. Based on an average daily trading volume, of 399,000 shares, the short-interest ratio is presently 2.4 days. Approximately 4.5% of the company's shares are sold short. View Eiger Biopharmaceuticals' Current Options Chain. Who are some of Eiger Biopharmaceuticals' key competitors? Some companies that are related to Eiger Biopharmaceuticals include Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Translate Bio (TBIO), Aerie Pharmaceuticals (AERI), AVITA MED LTD/S (RCEL), GENFIT S A/ADR (GNFT), Avrobio (AVRO), BAVARIAN NORDIC/S (BVNRY), Compugen (CGEN), Atara Biotherapeutics (ATRA), Proteon Therapeutics (PRTO), MeiraGTx (MGTX), Aptose Biosciences (APTO), DBV TECHNOLOGIE/S (DBVT) and Mesoblast (MESO). What other stocks do shareholders of Eiger Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger Biopharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Progenics Pharmaceuticals (PGNX), Gilead Sciences (GILD), Celldex Therapeutics (CLDX), Concert Pharmaceuticals (CNCE), Exelixis (EXEL) and Catalyst Pharmaceuticals (CPRX). Who are Eiger Biopharmaceuticals' key executives? Eiger Biopharmaceuticals' management team includes the following people: Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)Mr. James P. Shaffer, Chief Bus. Officer (Age 52)Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38) What is Eiger Biopharmaceuticals' stock symbol? Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR." How do I buy shares of Eiger Biopharmaceuticals? Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Eiger Biopharmaceuticals' stock price today? One share of EIGR stock can currently be purchased for approximately $6.74. How big of a company is Eiger Biopharmaceuticals? Eiger Biopharmaceuticals has a market capitalization of $165.53 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe. View additional information about Eiger Biopharmaceuticals. What is Eiger Biopharmaceuticals' official website? The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/. How can I contact Eiger Biopharmaceuticals? Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected] MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 398 (Vote Outperform)Underperform Votes: 275 (Vote Underperform)Total Votes: 673MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: What does a dividend yield signify to investors?
